Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$118.07
-2.2%		$110.93
$90.39
▼
$212.75
$26.49B0.833.86 million shs2.40 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$39.99
-4.4%		$37.20
$19.96
▼
$42.50
$30.23B1.238.29 million shs8.74 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$593.31
-0.4%		$540.58
$455.63
▼
$614.23
$25.37B0.49547,867 shs321,326 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
-2.22%+8.56%+21.99%-4.58%-39.26%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-4.44%+9.20%+19.91%+10.47%+87.57%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.39%+4.88%+9.18%+18.73%+28.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$118.07
-2.2%		$110.93
$90.39
▼
$212.75
$26.49B0.833.86 million shs2.40 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$39.99
-4.4%		$37.20
$19.96
▼
$42.50
$30.23B1.238.29 million shs8.74 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$593.31
-0.4%		$540.58
$455.63
▼
$614.23
$25.37B0.49547,867 shs321,326 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
-2.22%+8.56%+21.99%-4.58%-39.26%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-4.44%+9.20%+19.91%+10.47%+87.57%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.39%+4.88%+9.18%+18.73%+28.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
2.92
Moderate Buy$196.5266.45% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.6416.62% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4014.00% Upside

Current Analyst Ratings Breakdown

Latest IMGN, ROIV, INSM, and UTHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$660.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$700.00 ➝ $703.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$675.00 ➝ $700.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$697.00 ➝ $725.00
11/4/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$720.00
11/4/2026
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$220.00
11/4/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$728.00 ➝ $768.00
11/2/2026
Insmed, Inc. stock logo
INSM
Insmed
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
11/2/2026
Insmed, Inc. stock logo
INSM
Insmed
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$205.00 ➝ $201.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
Insmed, Inc. stock logo
INSM
Insmed
$606.42M42.71N/AN/A$3.31 per share35.67
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,497.04N/AN/A$6.36 per share6.29
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B7.94$32.85 per share18.06$147.36 per share4.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$2.82N/A190.44N/A-39.85%-96.38%-32.55%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5022.3918.683.9938.61%19.18%17.07%N/A

Latest IMGN, ROIV, INSM, and UTHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
10/29/2026Q3 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.3827-$0.46-$0.0773-$0.46$500.36 million$524.43 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
Insmed, Inc. stock logo
INSM
Insmed
0.77
2.86
2.59
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
16.72
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664219.38 million214.77 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721722.32 million658.76 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
November 13 at 1:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31194807
United Therapeutics Insider Sold Shares Worth $5,642,870, According to a Recent SEC Filing
November 12 at 5:24 PM  |  marketscreener.comM
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Company Stock
November 12 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-9500-shares-of-company-stock-2026-11-12/
Analysts Issue Forecasts for UTHR FY2026 Earnings
November 11 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-analysts-issue-forecasts-for-uthr-fy2026-earnings-2026-11-11/
United Therapeutics (NASDAQ:UTHR) Director Sells $701,800.00 in Stock
November 11 at 5:22 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-11-11/
HC Wainwright Initiates Coverage on United Therapeutics (NASDAQ:UTHR)
November 11 at 1:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190891
United Therapeutics (NASDAQ:UTHR) Stock: Insider Christopher Patusky Sells 1,210 Shares
November 10 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-stock-insider-christopher-patusky-sells-1210-shares-2026-11-10/
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 7,886 Shares of Stock
November 10 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-martine-rothblatt-sells-7886-shares-of-stock-2026-11-10/
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,362,845.00 in Stock
November 10 at 4:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-11-10/
Critical Comparison: United Therapeutics (NASDAQ:UTHR) vs. Black Diamond Therapeutics (NASDAQ:BDTX)
November 10 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31188888
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-ceo-sells-9500-shares-of-stock-2026-11-09/
United Therapeutics Corporation Announces Participation at Upcoming November 2026 Investor Conferences
November 9, 2026  |  biospace.comB
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
November 9, 2026  |  aol.comA
United Therapeutics (NASDAQ:UTHR) Now Covered by HC Wainwright
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-united-therapeutics-nasdaq-uthr-now-covered-by-hc-wainwright-2026-11-09/
4,954 United Therapeutics Corporation $UTHR Shares Acquired by University of Texas Texas AM Investment Management Co.
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-4954-united-therapeutics-corporation-uthr-shares-acquired-by-university-of-texas-texas-am-investment-management-co-2026-11-09/
12,583 Shares of United Therapeutics Corporation $UTHR Acquired by Hohimer Wealth Management LLC
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-12583-shares-of-united-therapeutics-corporation-uthr-acquired-by-hohimer-wealth-management-llc-2026-11-09/
United Therapeutics Corporation $UTHR Stock Holdings Reduced by Pictet Asset Management Holding SA
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-united-therapeutics-corporation-uthr-stock-holdings-reduced-by-pictet-asset-management-holding-sa-2026-11-09/
3,010 Shares of United Therapeutics Corporation $UTHR Purchased by Mirae Asset Global Investments Co. Ltd.
November 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3010-shares-of-united-therapeutics-corporation-uthr-purchased-by-mirae-asset-global-investments-co-ltd-2026-11-08/
Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,968,961.00 in Stock
November 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31186412
United Therapeutics Insider Sold Shares Worth $1,171,609, According to a Recent SEC Filing
November 6, 2026  |  marketscreener.comM
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 7,540 Shares of Stock
November 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-martine-rothblatt-sells-7540-shares-of-stock-2026-11-06/

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Insmed stock logo

Insmed NASDAQ:INSM

$118.07 -2.68 (-2.22%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$117.28 -0.79 (-0.67%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$39.99 -1.86 (-4.44%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$39.90 -0.09 (-0.23%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$593.31 -2.35 (-0.39%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$595.95 +2.64 (+0.44%)
As of 08:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas